You are browsing articles on the topic of Anticoagulation Archives - CardioExchange

Avatar of Larry Husten, PHD

No Advantage to Adding Inferior Vena Cava Filters to Anticoagulation (28 Apr 2015)

News

Despite a lack of supporting evidence  many patients with acute venous thromboembolism (VTE) receive inferior vena cava filters to prevent pulmonary embolism (PE). Now a new study published in JAMA offers no evidence of benefit for the use of these devices in a high-risk population already receiving anticoagulant drugs. A group of French physicians randomized nearly…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.

Avatar of Larry Husten, PHD

FDA Approves Watchman Left Atrial Appendage Closure Device for AF (14 Mar 2015)

News

The FDA has approved Boston Scientific’s long-delayed Watchman Left Atrial Appendage Closure Device. According to the company, the Watchman is indicated as an alternative to long-term warfarin therapy for the reduction of thromboembolism from the left atrial appendage in patients with non-valvular atrial fibrillation at increased risk for stroke and systemic embolism. Although an alternative to…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.

Avatar of Larry Husten, PHD

Increased Risk with NSAIDs Following Myocardial Infarction (24 Feb 2015)

News

The cardiovascular safety of nonsteroidal anti-inflammatory drugs (NSAIDs) like ibuprofen and diclofenac  has been the subject of considerable uncertainty and controversy. Now a new study published in JAMA raises specific concerns about the safety of these drugs in the highly vulnerable population of people who have had a recent myocardial infarction. Using data from several linked…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.

Avatar of CardioExchange Editors, Staff

Can Clopidogrel Get Along with Proton Pump Inhibitors? (13 Feb 2015)

Voices

CardioExchange Editors, Staff

Are there clinically significant interactions between clopidogrel, proton pump inhibitors, and other drugs?

Avatar of Larry Husten, PHD

Ticagrelor Improves Outcomes After Myocardial Infarction (14 Jan 2015)

News

For the first time, a very large trial has shown that dual antiplatelet therapy (DAPT) improves cardiovascular outcomes when given to patients 1 to 3 years after a myocardial infarction. Because DAPT has been shown previously to reduce the high risk of recurrent events for up to a year following an MI, it is considered to be standard…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.

Avatar of Larry Husten, PHD

FDA Approves New Oral Anticoagulant from Daiichi Sankyo (9 Jan 2015)

News

And then there were four. Late Thursday the FDA announced that it had approved edoxaban, the new oral anticoagulant manufactured by Daiichi Sankyo. The drug will be marketed under the brand name of Savaysa and joins three other new drugs in the large and important new oral anticoagulant marketplace: dabigatran (Pradaxa), rivaroxaban (Xarelto), and apixaban (Eliquis). All four drugs…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.

Avatar of Sanjay

New Anticoagulant Spotlights Major Role for the Intrinsic Pathway (8 Dec 2014)

Voices

Sanjay Kaul, MD and Ethan J Weiss, M.D.

Sanjay Kaul and Ethan Weiss discuss an entirely new approach to anticoagulation.

Avatar of Jean Costello, CardioExchange Staff

Agent Could Potentially Reverse Anticoagulation Associated with Edoxaban (6 Nov 2014)

News

PER977 — a cation that binds to all of the new oral anticoagulants and heparin — may help reverse the anticoagulant effects of edoxaban, according to results of an industry-conducted trial published in the New England Journal of Medicine. Edoxaban, an oral factor Xa inhibitor, was recently recommended for approval by an FDA advisory panel….

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.

Avatar of Larry Husten, PHD

AF Patients at Increased Risk for Silent Strokes (3 Nov 2014)

News

The increased risk of stroke in people with atrial fibrillation (AF) is well known, and this stroke risk is, of course, linked to an increased risk of cognitive impairment and dementia. Less well known is that people with AF have an increased risk for cognitive impairment independent of their stroke risk. Now a new study…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.

Avatar of Larry Husten, PHD

Economic Study Finds VTE Prophylaxis with Low-Molecular-Weight Heparin Cost Effective (3 Nov 2014)

News

Critically ill patients in the hospital are at high risk for developing venous thromboembolism (VTE). The 2011 PROTECT trial compared the two most common drug strategies used to prevent VTE — unfractionated heparin (UFH) and dalteparin, a low-molecular-weight heparin (LMWH) —  and found no difference between the two groups in the primary endpoint of the trial, leg deep-vein thrombosis….

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.